Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc.verified

SLRX

Price:

$1.49

Market Cap:

$2.15M

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea;...[Read more]

Industry

Biotechnology

IPO Date

2015-01-29

Stock Exchange

NASDAQ

Ticker

SLRX

The Current Ratio as of September 2024 (TTM) for Salarius Pharmaceuticals, Inc. (SLRX) is 2.98

According to Salarius Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.98. This represents a change of -23.06% compared to the average of 3.88 of the last 4 quarters.

Salarius Pharmaceuticals, Inc. (SLRX) Historical Current Ratio (quarterly & annually)

How has SLRX Current Ratio performed in the past?

The mean historical Current Ratio of Salarius Pharmaceuticals, Inc. over the last ten years is 12.89. The current 2.98 Current Ratio has changed 2.21% with respect to the historical average. Over the past ten years (40 quarters), SLRX's Current Ratio was at its highest in in the March 2015 quarter at 78.72. The Current Ratio was at its lowest in in the September 2019 quarter at 1.11.

Quarterly (TTM)
Annual

Average

12.89

Median

7.59

Minimum

1.42

Maximum

34.40

Salarius Pharmaceuticals, Inc. (SLRX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Salarius Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 302.04%

Maximum Annual Current Ratio = 34.40

Minimum Annual Increase = -84.80%

Minimum Annual Current Ratio = 1.42

Quarterly (TTM)
Annual
YearCurrent RatioChange
20235.0247.44%
20223.40-76.18%
202114.29150.86%
20205.70302.04%
20191.42-84.80%
20189.3258.85%
20175.87-63.39%
201616.03-52.16%
201533.50-2.61%

Salarius Pharmaceuticals, Inc. (SLRX) Average Current Ratio

How has SLRX Current Ratio performed in the past?

The current Current Ratio of Salarius Pharmaceuticals, Inc. (SLRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

7.57

5-year avg

5.96

10-year avg

12.89

Salarius Pharmaceuticals, Inc. (SLRX) Current Ratio vs. Peers

How is SLRX’s Current Ratio compared to its peers?

Salarius Pharmaceuticals, Inc.’s Current Ratio is greater than Akari Therapeutics, Plc (0.58), greater than Axcella Health Inc. (0.80), less than Magenta Therapeutics, Inc. (14.64), less than Histogen Inc. (4.05), greater than Timber Pharmaceuticals, Inc. (0.50), less than Artelo Biosciences, Inc. (14.58), less than Nutriband Inc. (6.57), less than Aileron Therapeutics, Inc. (4.69), greater than First Wave BioPharma, Inc. (1.21), less than SAB Biotherapeutics, Inc. (5.24), greater than Vaccinex, Inc. (0.42), greater than GeoVax Labs, Inc. (0.60), less than Corvus Pharmaceuticals, Inc. (3.62), less than Mereo BioPharma Group plc (6.07), greater than Affimed N.V. (2.71), less than Pieris Pharmaceuticals, Inc. (3.95), less than Artelo Biosciences, Inc. (14.58), less than Fresh Tracks Therapeutics, Inc. (6.98),

Build a custom stock screener for Salarius Pharmaceuticals, Inc. (SLRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Salarius Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Salarius Pharmaceuticals, Inc. (SLRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Salarius Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Current Ratio?

How can you use the Current Ratio?

What is Salarius Pharmaceuticals, Inc.'s Current Ratio?

How is the Current Ratio calculated for Salarius Pharmaceuticals, Inc. (SLRX)?

What is the highest Current Ratio for Salarius Pharmaceuticals, Inc. (SLRX)?

What is the 3-year average Current Ratio for Salarius Pharmaceuticals, Inc. (SLRX)?

What is the 5-year average Current Ratio for Salarius Pharmaceuticals, Inc. (SLRX)?

How does the current Current Ratio for Salarius Pharmaceuticals, Inc. (SLRX) compare to its historical average?